International Flavors (IFF) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

International Flavors (IFF) reported Q2 2025 revenue of $2.76 billion, a 4.3% year-over-year decline, yet it surpassed the Zacks consensus estimate by 1.19%, with EPS of $1.15 also beating estimates by 3.6%. While Health & Biosciences and Food Ingredients net sales exceeded expectations, the Pharma Solutions segment experienced a significant 58.8% year-over-year revenue decrease. Despite the overall earnings beat and a Zacks #2 (Buy) rank, IFF's shares have underperformed the S&P 500 over the past month, declining 6.5%.

Analysis

International Flavors (IFF) presented a mixed financial picture in its Q2 2025 earnings report, beating consensus estimates on both revenue and earnings while exhibiting underlying weakness. The company reported revenue of $2.76 billion, a 1.19% beat against the $2.73 billion estimate, and an EPS of $1.15, surpassing the $1.11 consensus by 3.6%. However, these figures represent year-over-year declines, with revenue down 4.3% and EPS slightly lower than the $1.16 reported in the prior-year period. A granular look at segment performance reveals a significant divergence: the Health & Biosciences and Food Ingredients divisions showed resilience, exceeding their respective net sales forecasts. Notably, Food Ingredients also delivered a strong beat on Adjusted Operating EBITDA ($124 million vs. $111.08 million estimated), indicating robust profitability. Conversely, the Pharma Solutions segment is a major concern, with its net sales plummeting 58.8% year-over-year to $103 million, substantially missing the $120.11 million analyst estimate. The Scent and Taste segments also posted slight misses on both revenue and EBITDA estimates. This internal weakness likely contributes to the stock's recent underperformance, with a -6.5% return over the past month, lagging the S&P 500 composite's +1% gain, despite a current Zacks Rank #2 (Buy) designation.

Key Decisions for Investors

• Investors should look beyond the headline earnings beat and focus on the severe 58.8% year-over-year revenue collapse in the Pharma Solutions segment, as this represents a material drag on the company's overall growth profile.
• The relative strength and profitability in the core Food Ingredients segment, which beat EBITDA estimates significantly, should be weighed as a potential buffer against weakness in other divisions.
• Given the stock's recent underperformance against the broader market, it is prudent to seek clarity on management's strategy to stabilize the struggling Pharma Solutions unit before acting on the quantitative Zacks #2 (Buy) rating.